NASDAQ · Biotechnology

Athira Pharma, Inc. (ATHA) Stock

$6.75 -6.12% NASDAQ: ATHA Healthcare

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier.

Valuation

MetricValue
Price$6.75
Market Cap$26.62M
P/E Ratio-0.28
P/B Ratio0.73
P/S Ratio0.00
EPS (TTM)$-24.70
52-Week High$8.36
52-Week Low$2.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-381.01%
ROA-180.77%
ROCE-170.77%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio10.38

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-64.0M$-104.0M$-125.0M$-101.0M$-102.0M
Net Profit$-55.0M$-96.0M$-118.0M$-97.0M$-106.0M
EPS$-14.90$-25.30$-30.90$-25.20$-24.70
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$332.0M$258.0M$160.0M$59.0M$92.0M
Total Liabilities$11.0M$23.0M$30.0M$14.0M$64.0M
Cash$111.0M$96.0M$91.0M$48.0M$69.0M
Borrowings$2.0M$2.0M$2.0M$1.0M$1.0M

Latest News

Atha Energy Announces Second Amendment to Royalty Agreement With the New Saskatchewan Syndicate ACCESS Newswire · Jul 16, 2026 ATHA Energy Announces Corporate Activities Update ACCESS Newswire · Jul 13, 2026 ATHA Energy Reports Widest Intersection to Date at Rib North Discovery with 37 m of Composite Uranium Mineralization in Ribn-DD-003 – Multiple Drillholes Demonstrating Continuity of Uranium Mineralization ACCESS Newswire · Jul 9, 2026 ATHA Energy Makes Major New High-Grade Discovery along the Lac 50 Corridor - Intersects 11.5 m of Composite Uranium Mineralization Including 1.6 m of Near Continuous High-Grade 4 km Along Strike from Lac 50 Deposit Area ACCESS Newswire · Jul 8, 2026 OTC Markets Group Welcomes ATHA Energy Corp. to OTCQX GlobeNewswire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-43.0M$-72.0M$-101.0M$-97.0M$-46.0M
Investing Cash Flow$-6.0M$57.0M$95.0M$55.0M$-16.0M
Financing Cash Flow$0$0$0$0$82.0M
Net Cash Flow$50.0M$-15.0M$-5.0M$-42.0M$21.0M
Free Cash Flow$-45.0M$-74.0M$-101.0M$-97.0M$-46.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.03
FCF Yield-155.93%
Quick Ratio10.38
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADTX $0.01 -77.22% -0.01 $318 0.00%
APLMApollomics, Inc. $18.76 +2.99% -2.41 $20.69M 0.00%
CRIS $4.69 -4.09% -0.35 $9.14M 0.00%
CTXR $0.57 -9.81% -0.68 $6.37M 0.00%
DARE $1.32 +3.13% -1.94 $12.57M 0.00%

About Athira Pharma, Inc.

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.

Athira Pharma, Inc. is headquartered in US.

Athira Pharma, Inc. (ATHA) stock trades at $6.75 with a market capitalization of $26.62M. The stock is valued at a price-to-earnings (P/E) ratio of -0.28, price-to-book of 0.73, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.20 and $8.36, and currently trades 19.3% below its 52-week high.

On profitability, Athira Pharma, Inc. generates a return on equity (ROE) of -381.01%, return on capital employed of -170.77%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.athira.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides